Lipitor, Atorvastatin

Lipitor, Atorvastatin Newswire (Page 5)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 5)

Results 81 - 100 of 1,668 in Lipitor, Atorvastatin (generic)

  1. Pfizer confronts surge of lawsuits over LipitorRead the original story w/Photo

    Aug 8, 2014 | Business Insurance

    Pharmaceutical giant Pfizer Inc. is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its blockbuster anti-cholesterol drug Lipitor but never properly warned the public.

    Comment?

  2. Time To Panic Over Lipitor Litigation?Read the original story

    Aug 11, 2014 | Seeking Alpha

    Lipitor is the best selling prescription drug ever and one of the most advertised drugs.

    Comment?

  3. New Research Finds Cholesterol Drugs No Match for Mesothelioma,...Read the original story w/Photo

    Aug 11, 2014 | PRWeb

    Continuous administration of atorvastatin did not alter the rate of disease development nor increase the length of time that mice survived.

    Comment?

  4. Lipitor Lawsuits Among Women Soar in Past 5 MonthsRead the original story

    Aug 10, 2014 | Journal Watch

    Lawsuits by U.S. women who blame Lipitor for their type 2 diabetes have soared over the past 5 months, from 56 to nearly 1000 cases representing 4000 women, according to a Reuters investigation.

    Comment?

  5. Thousands of women sue Pfizer over LipitorRead the original story w/Photo

    Aug 10, 2014 | Examiner.com

    Thousands of women sue Pfizer over Lipitor . More than 4,000 women in the United States filed lawsuits in federal court claiming Lipitor caused them to develop Type-2 diabetes .

    Comment?

  6. Synthesis of deuterium-labeled atorvastatin and its metabolites for...Read the original story

    Aug 9, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  7. Cholesterol Drugs' Benefits Far Outweigh Side Effects, Review FindsRead the original story w/Photo

    Aug 5, 2014 | Newsday

    The benefits of long-term use of cholesterol-lowering statin drugs greatly outweigh the risks, according to a review of research published over 20 years.

    Comment?

  8. Drug giant faces flood of lawsuits over LipitorRead the original story w/Photo

    Aug 8, 2014 | Independent.ie

    In the past five months the number of cases has shot up from 56 to almost 1,000.

    Comment?

  9. Lipitor Lawsuits, Alleging Link To Type 2 Diabetes, Increase Dramatically Over The Past 5 MonthsRead the original story w/Photo

    Aug 8, 2014 | Medical Daily

    The number of lawsuits filed by women in the US who say taking Lipitor gave them type-2 diabetes rose from just 56 to nearly 1,000 over the past five months alone.

    Comment?

  10. Pfizer Lipitor Diabetes in Women Lawsuit UpdateRead the original story

    Aug 8, 2014 | Personal Injury Law News

    Pfizer, one of the world's largest pharmaceutical companies, is facing a surge lawsuits by women who allege that the drug manufacturer knew about serious diabetes side effects of its anti-cholesterol medication Lipitor but failed to warn the patients and doctors.

    Comment?

  11. Business-News-Schedule at 1230 GMT / 8.30 Am EtRead the original story

    Aug 8, 2014 | Reuters

    World shares and the dollar tumble and oil and gold jump after U.S. President Barack Obama authorises targeted air strikes in Iraq, stoking fears of another drawn-out conflict in the region.

    Comment?

  12. Statins May Aid Survival From Colon CancerRead the original story w/Photo

    Aug 4, 2014 | Health.com

    Statins, the widely used cholesterol-lowering drugs, may also boost colorectal cancer survival, according to a new U.K. study.

    Comment?

  13. Atorvastatin calcium plus amlodipine for the treatment of hypertension.Read the original story

    Aug 4, 2014 | CiteULike

    Hypertension and dyslipemia are two of the major modifiable cardiovascular risk factors, determinants in the development of cerebrovascular and coronary heart disease .

    Comment?

  14. Combined Administration of RG7652, a Recombinant Human Monoclonal...Read the original story

    Aug 4, 2014 | Toxicological Sciences

    To whom correspondence should be addressed at: Genentech Inc., MS no. 59, South San Francisco, CA 94080.

    Comment?

  15. Guideline Critics Shift Attacks From Beta Blockers To StatinsRead the original story w/Photo

    Aug 1, 2014 | Forbes.com

    With the release today of updated European and US guidelines the ongoing controversy regarding beta-blockers appears to be resolved.

    Comment?

  16. Sanofi and Regeneron report positive top-line results from nine phase ...Read the original story w/Photo

    Aug 1, 2014 | Medical News Today

    Sanofi and Regeneron Pharmaceuticals, Inc. have announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator.

    Comment?

  17. Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of AlirocumabRead the original story

    Jul 29, 2014 | Drugs.com

    July 30, 2014 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator.

    Comment?

  18. Lawsuit Funding For Lipitor and Crestor Diabetes LawsuitsRead the original story

    Jul 31, 2014 | PRWeb

    Lawsuit Funding Network has secured investors to assist victims who have developed Type-II Diabetes while either taking Lipitor or Crestor.

    Comment?

  19. Positive Results Reported From Nine Phase III Trials of Alirocumab in HypercholesterolemiaRead the original story

    Jul 30, 2014 | P&T Community

    Nine new phase III studies of alirocumab in patients with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared with placebo or an active comparator.

    Comment?

  20. Regeneron Pharmaceuticals, Inc., Sanofi (France) Drug Alirocumab Cuts ...Read the original story w/Photo

    Jul 30, 2014 | BioSpace

    Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia Primary Efficacy Endpoints Met In All Nine New Trials Of Investigational PCSK9 Inhibitor /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that nine new Phase 3 ODYSSEY trials of alirocumab in ... (more)

    Comment?